Physician profile
Vera Y Hou
NPI 1750308565
$1,786.76
in general payments reported to CMS, 2019-2025
16 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.94 · 2022: $13.24 · 2023: $600 · 2024: $696 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.64 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $315.26 | 2023-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $172.71 | 2023-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $150.08 | 2023-2025 | Farxiga, Fasenra |
| Abbott Laboratories | $145.67 | 2023 | Cardiomems |
| Scpharmaceuticals INC. | $137.05 | 2024-2025 | |
| Cvrx, INC. | $134.94 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2024 | Camzyos |
| Abiomed | $115.62 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $33.52 | 2021-2025 | Opsumit, Uptravi |
| Pfizer INC. | $32.88 | 2023-2024 | |
| Astellas Pharma US INC | $25.36 | 2025 | Cresemba |
| Novartis Pharmaceuticals Corporation | $22.65 | 2023 | |
| Bridgebio Pharma, INC. | $19.00 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $17.77 | 2025 | Nucala |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.62 | 2024 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.